Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

PURPOSE: To compare the efficacy and safety of anti-PD1 checkpoint inhibitor plus chemotherapy with anti-PD1 checkpoint inhibitor alone in recurrent and metastatic nasopharyngeal carcinoma (R/M NPC) progressing after first or subsequent-line therapy. METHODS AND MATERIALS: A total of 67 patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ting, Zhang, Qun, Jin, Qi-Feng, Hua, Yong-Hong, Chen, Xiao-Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750692/
https://www.ncbi.nlm.nih.gov/pubmed/33341487
http://dx.doi.org/10.1016/j.tranon.2020.100989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750692/
https://www.ncbi.nlm.nih.gov/pubmed/33341487
http://dx.doi.org/10.1016/j.tranon.2020.100989

Ejemplares similares